Dacryocystitis Market Size and Share
| Study Period | 2019 - 2030 |
| Base Year For Estimation | 2024 |
| Forecast Data Period | 2025 - 2030 |
| Historical Data Period | 2019 - 2023 |
| CAGR | 4.20% |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Dacryocystitis Market Analysis by Mordor Intelligence
The Dacryocystitis Market is expected to register a CAGR of 4.2% during the forecast period.
Certain factors that are driving the market growth include a rise in the prevalence of eye infections and increasing clinical research and subsequent new product launches.
Dacryoadenitis is an inflammation of the lacrimal gland. Infections are rare and may be acute or chronic. Patients with acute dacryoadenitis suffer from a tender area of erythema and swelling in the lateral part of the upper lid. It may lead to preseptal or orbital cellulitis or may suppurate into an abscess.
As per the study titled 'Fungal infections of the eye', fungal dacryocystitis accounts for approximately 5% of all acquired dacryocystitis and around 14% of cases of congenital dacryocystitis. Women are affected more frequently with all forms of dacryocystitis than men, probably because of anatomically narrower nasolacrimal ducts. It mostly affects individuals in their 50s or 60s.
Global Dacryocystitis Market Trends and Insights
Acute Dacryocystitis Holds Significant Share in the Dacryocystitis Market
Dacryocystitis can be acute or chronic and congenital or acquired. Symptoms of acute dacryocystitis start suddenly and often include fever and pus from the eye. Bacterial infections are usually the cause of acute dacryocystitis, and antibiotic treatment usually resolves the infection within a few days. People with acute dacryocystitis often experience more severe symptoms than those with chronic dacryocystitis. However, in all age groups, acute dacryocystitis generally resolves quickly after taking oral antibiotics.
North America Dominates the Dacryocystitis Market
The United States has witnessed a considerable rise in the number of dacryocystitis patients. According to the 2019 study (Grant D Gilliland et al), in adults, females are afflicted more commonly by dacryocystitis. Most studies demonstrate that 70-83% of cases of dacryocystitis occur in females. Congenital dacryocystitis occurs with equal frequency in both sexes. Moreover, the ease in the US government's regulations and the availability of funds from various organizations, like the National Institute of Health, have provided the potential for researchers to invest more in drug discovery for the disease.
Competitive Landscape
The dacryocystitis market is competitive and consists of a few major players. Companies like Aurobindo Pharma, Bess Medizintechnik GmbH, FCI Ophthalmics, Glaxosmithkline PLC, Kaneka Corporation, Mylan NV, Nosch, Orex Pharma Pvt Ltd, and Pfizer Inc., hold the substantial share in the market.
Dacryocystitis Industry Leaders
-
Pfizer Inc.
-
Aurobindo Pharma
-
Orex Pharma Pvt Ltd
-
Nosch
-
Mylan NV
- *Disclaimer: Major Players sorted in no particular order
Global Dacryocystitis Market Report Scope
As per the scope of the report, dacryocystitis refers to an infection of the tear sac (lacrimal sac) in the inner corner of the eye. It causes pain, redness, and swelling over the inner aspect of the lower eyelid and epiphora.
| Acute |
| Chronic |
| Other Indications |
| Institutional Sales |
| Retail Sales |
| North America | United States |
| Canada | |
| Mexico | |
| Europe | Germany |
| United Kingdom | |
| France | |
| Italy | |
| Spain | |
| Rest of Europe | |
| Asia-Pacific | China |
| Japan | |
| India | |
| Australia | |
| South Korea | |
| Rest of Asia-Pacific | |
| Middle-East and Africa | GCC |
| South Africa | |
| Rest of Middle-East and Africa | |
| South America | Brazil |
| Argentina | |
| Rest of South America |
| By Indication | Acute | |
| Chronic | ||
| Other Indications | ||
| By Distribution Channel | Institutional Sales | |
| Retail Sales | ||
| By Geography | North America | United States |
| Canada | ||
| Mexico | ||
| Europe | Germany | |
| United Kingdom | ||
| France | ||
| Italy | ||
| Spain | ||
| Rest of Europe | ||
| Asia-Pacific | China | |
| Japan | ||
| India | ||
| Australia | ||
| South Korea | ||
| Rest of Asia-Pacific | ||
| Middle-East and Africa | GCC | |
| South Africa | ||
| Rest of Middle-East and Africa | ||
| South America | Brazil | |
| Argentina | ||
| Rest of South America | ||
Key Questions Answered in the Report
What is the current Dacryocystitis Market size?
The Dacryocystitis Market is projected to register a CAGR of 4.2% during the forecast period (2025-2030)
Who are the key players in Dacryocystitis Market?
Pfizer Inc., Aurobindo Pharma, Orex Pharma Pvt Ltd, Nosch and Mylan NV are the major companies operating in the Dacryocystitis Market.
Which is the fastest growing region in Dacryocystitis Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2025-2030).
Which region has the biggest share in Dacryocystitis Market?
In 2025, the North America accounts for the largest market share in Dacryocystitis Market.
What years does this Dacryocystitis Market cover?
The report covers the Dacryocystitis Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Dacryocystitis Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.
Page last updated on:
Dacryocystitis Market Report
Statistics for the 2025 Dacryocystitis market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Dacryocystitis analysis includes a market forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.
